STOCK TITAN

[6-K] Pearson plc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Scienture Holdings, Inc. (formerly TRxADE Health/TRXADE Group) filed a Form D to report a private placement of equity securities under Reg D Rule 506(b) and Securities Act §4(a)(5).

  • Offering size: up to $3.0 million; $1.3 million (43%) has been sold since the first closing on 18 Jul 2025.
  • Investors: 4 purchasers to date; only accredited investors indicated.
  • Securities: equity; minimum subscription $50,000.
  • Use of proceeds: general working capital; $0 earmarked for payments to officers/directors.
  • Offering costs: no sales commissions, broker-dealer involvement, or finder’s fees disclosed.
  • Issuer details: Delaware corporation (>5 yrs old); principal office Commack, NY; industry classification Pharmaceuticals.
  • Issuer size: revenue and asset ranges “Decline to disclose.”
  • Duration: offering expected to close within one year.

The filing signals an early-stage capital raise that, while modest in scale, strengthens liquidity without immediate shareholder dilution from brokerage fees.

Scienture Holdings, Inc. (precedentemente TRxADE Health/TRXADE Group) ha presentato un Modulo D per segnalare un collocamento privato di titoli azionari ai sensi del Regolamento D, Regola 506(b) e della Sezione 4(a)(5) del Securities Act.

  • Dimensione dell'offerta: fino a 3,0 milioni di dollari; 1,3 milioni di dollari (43%) sono stati venduti dalla prima chiusura il 18 luglio 2025.
  • Investitori: 4 acquirenti finora; indicati solo investitori accreditati.
  • Strumenti finanziari: azioni; sottoscrizione minima di 50.000 dollari.
  • Utilizzo dei proventi: capitale circolante generale; 0 dollari destinati a pagamenti a dirigenti o membri del consiglio.
  • Costi dell'offerta: nessuna commissione di vendita, coinvolgimento di broker-dealer o commissioni per intermediari dichiarate.
  • Dettagli sull'emittente: società del Delaware (>5 anni); sede principale a Commack, NY; classificazione industriale Farmaceutica.
  • Dimensione dell'emittente: ricavi e patrimonio indicati con la dicitura “Rifiuto di divulgare.”
  • Durata: l'offerta dovrebbe chiudersi entro un anno.

La comunicazione indica una raccolta di capitale in fase iniziale che, sebbene modesta, rafforza la liquidità senza causare una diluizione immediata degli azionisti dovuta a commissioni di intermediazione.

Scienture Holdings, Inc. (anteriormente TRxADE Health/TRXADE Group) presentó un Formulario D para reportar una colocación privada de valores de capital bajo la Regla 506(b) del Reglamento D y la Sección 4(a)(5) de la Ley de Valores.

  • Tamaño de la oferta: hasta 3,0 millones de dólares; se han vendido 1,3 millones de dólares (43%) desde el primer cierre el 18 de julio de 2025.
  • Inversores: 4 compradores hasta la fecha; solo se indican inversores acreditados.
  • Valores: capital; suscripción mínima de 50.000 dólares.
  • Uso de los fondos: capital de trabajo general; 0 dólares destinados a pagos a funcionarios o directores.
  • Costos de la oferta: no se revelaron comisiones de venta, participación de corredores o honorarios por intermediarios.
  • Detalles del emisor: corporación de Delaware (>5 años); oficina principal en Commack, NY; clasificación industrial Farmacéutica.
  • Tamaño del emisor: rangos de ingresos y activos con la indicación “Se niega a divulgar.”
  • Duración: se espera que la oferta cierre dentro de un año.

La presentación señala una recaudación de capital en etapa temprana que, aunque modesta en escala, fortalece la liquidez sin una dilución inmediata de los accionistas debido a comisiones de corretaje.

Scienture Holdings, Inc. (이전 명칭 TRxADE Health/TRXADE Group)는 Reg D 규칙 506(b) 및 증권법 §4(a)(5)에 따라 사모 주식 발행을 보고하기 위해 Form D를 제출했습니다.

  • 공모 규모: 최대 300만 달러; 130만 달러(43%)가 2025년 7월 18일 첫 클로징 이후 판매되었습니다.
  • 투자자: 현재까지 4명의 구매자; 공인 투자자만 명시됨.
  • 증권 종류: 주식; 최소 청약금액 5만 달러.
  • 자금 사용처: 일반 운전자본; 임원/이사에 대한 지급액은 0달러로 책정됨.
  • 공모 비용: 판매 수수료, 중개인 참여 또는 소개 수수료는 공개되지 않음.
  • 발행자 정보: 델라웨어 법인(5년 이상); 본사 뉴욕주 코맥 소재; 산업 분류 제약.
  • 발행자 규모: 매출 및 자산 범위는 “공개 거부”로 표시됨.
  • 기간: 공모는 1년 이내 종료 예정.

이번 제출은 규모는 크지 않지만 중개 수수료로 인한 즉각적인 주주 희석 없이 유동성을 강화하는 초기 단계 자본 조달을 나타냅니다.

Scienture Holdings, Inc. (anciennement TRxADE Health/TRXADE Group) a déposé un Formulaire D pour signaler un placement privé de titres de capitaux propres en vertu de la Règle 506(b) du règlement D et de l'article 4(a)(5) du Securities Act.

  • Taille de l'offre : jusqu'à 3,0 millions de dollars ; 1,3 million de dollars (43 %) ont été vendus depuis la première clôture le 18 juillet 2025.
  • Investisseurs : 4 acheteurs à ce jour ; seuls des investisseurs accrédités sont mentionnés.
  • Titres : actions ; souscription minimale de 50 000 dollars.
  • Utilisation des fonds : fonds de roulement général ; 0 dollar destiné aux paiements aux dirigeants/directeurs.
  • Coûts de l'offre : aucune commission de vente, implication de courtiers ou frais d'intermédiaire divulgués.
  • Détails de l'émetteur : société du Delaware (>5 ans) ; siège principal à Commack, NY ; classification industrielle Pharmaceutique.
  • Taille de l'émetteur : revenus et actifs indiqués comme « Refus de divulguer ».
  • Durée : l'offre devrait se clôturer dans un délai d'un an.

Le dépôt signale une levée de fonds en phase initiale qui, bien que modeste, renforce la liquidité sans dilution immédiate des actionnaires due aux frais de courtage.

Scienture Holdings, Inc. (ehemals TRxADE Health/TRXADE Group) reichte ein Formular D ein, um eine Privatplatzierung von Eigenkapitalwertpapieren gemäß Reg D Regel 506(b) und Securities Act §4(a)(5) zu melden.

  • Angebotsgröße: bis zu 3,0 Millionen US-Dollar; 1,3 Millionen US-Dollar (43 %) wurden seit dem ersten Abschluss am 18. Juli 2025 verkauft.
  • Investoren: Bisher 4 Käufer; nur akkreditierte Investoren angegeben.
  • Wertpapiere: Eigenkapital; Mindestzeichnung 50.000 US-Dollar.
  • Verwendung der Erlöse: allgemeines Betriebskapital; 0 US-Dollar für Zahlungen an leitende Angestellte/Vorstände vorgesehen.
  • Angebotskosten: keine Verkaufsprovisionen, Broker-Dealer-Beteiligung oder Vermittlungsgebühren angegeben.
  • Emittentendetails: Delaware-Gesellschaft (>5 Jahre alt); Hauptsitz in Commack, NY; Branchenklassifikation Pharmazeutika.
  • Emittentengröße: Umsatz- und Vermögensangaben mit dem Hinweis „Keine Angabe“.
  • Dauer: Angebot soll innerhalb eines Jahres abgeschlossen werden.

Die Einreichung signalisiert eine Kapitalaufnahme in einer frühen Phase, die zwar moderat ist, aber die Liquidität stärkt, ohne eine unmittelbare Verwässerung der Aktionäre durch Maklergebühren.

Positive
  • $1.3 million already raised, demonstrating investor interest and partially de-risking the capital raise
  • Offering incurs no sales commissions or finder’s fees, maximizing net proceeds
  • No proceeds allocated to insiders, reducing conflict-of-interest concerns
Negative
  • Issuer declines to disclose revenue and asset size, limiting financial transparency
  • Remaining $1.7 million still to be raised; completion risk remains
  • Minimum investment of $50,000 may narrow the investor pool

Insights

TL;DR: $3 m Rule 506(b) equity raise, 43% funded, no fees—efficient but small.

This Form D shows Scienture seeking a modest $3 m to fund pharma operations. Completing $1.3 m with only four investors suggests access to a focused accredited network and lowers marketing overhead. Absence of commissions preserves proceeds, and zero insider payments indicates funds will largely reach operations. However, the company declines to reveal revenue, implying either an early-stage profile or strategic opacity, which may increase diligence requirements for prospective investors. Overall impact is limited to private holders; public-market investors gain minimal new financial insight.

TL;DR: Clean governance signals—no broker, no insider payouts, standard exemptions.

Scienture complies with Rule 506(b) and §4(a)(5), avoiding general solicitation and limiting buyers to accredited investors—reducing regulatory friction. Listing five directors/officers provides transparency, and the statement that no proceeds will go to insiders mitigates related-party concerns. Yet, declining to disclose revenue limits the market’s ability to assess capitalization needs. Given the offering’s small size and lack of leverage, I view governance risk as low but information risk as moderate.

Scienture Holdings, Inc. (precedentemente TRxADE Health/TRXADE Group) ha presentato un Modulo D per segnalare un collocamento privato di titoli azionari ai sensi del Regolamento D, Regola 506(b) e della Sezione 4(a)(5) del Securities Act.

  • Dimensione dell'offerta: fino a 3,0 milioni di dollari; 1,3 milioni di dollari (43%) sono stati venduti dalla prima chiusura il 18 luglio 2025.
  • Investitori: 4 acquirenti finora; indicati solo investitori accreditati.
  • Strumenti finanziari: azioni; sottoscrizione minima di 50.000 dollari.
  • Utilizzo dei proventi: capitale circolante generale; 0 dollari destinati a pagamenti a dirigenti o membri del consiglio.
  • Costi dell'offerta: nessuna commissione di vendita, coinvolgimento di broker-dealer o commissioni per intermediari dichiarate.
  • Dettagli sull'emittente: società del Delaware (>5 anni); sede principale a Commack, NY; classificazione industriale Farmaceutica.
  • Dimensione dell'emittente: ricavi e patrimonio indicati con la dicitura “Rifiuto di divulgare.”
  • Durata: l'offerta dovrebbe chiudersi entro un anno.

La comunicazione indica una raccolta di capitale in fase iniziale che, sebbene modesta, rafforza la liquidità senza causare una diluizione immediata degli azionisti dovuta a commissioni di intermediazione.

Scienture Holdings, Inc. (anteriormente TRxADE Health/TRXADE Group) presentó un Formulario D para reportar una colocación privada de valores de capital bajo la Regla 506(b) del Reglamento D y la Sección 4(a)(5) de la Ley de Valores.

  • Tamaño de la oferta: hasta 3,0 millones de dólares; se han vendido 1,3 millones de dólares (43%) desde el primer cierre el 18 de julio de 2025.
  • Inversores: 4 compradores hasta la fecha; solo se indican inversores acreditados.
  • Valores: capital; suscripción mínima de 50.000 dólares.
  • Uso de los fondos: capital de trabajo general; 0 dólares destinados a pagos a funcionarios o directores.
  • Costos de la oferta: no se revelaron comisiones de venta, participación de corredores o honorarios por intermediarios.
  • Detalles del emisor: corporación de Delaware (>5 años); oficina principal en Commack, NY; clasificación industrial Farmacéutica.
  • Tamaño del emisor: rangos de ingresos y activos con la indicación “Se niega a divulgar.”
  • Duración: se espera que la oferta cierre dentro de un año.

La presentación señala una recaudación de capital en etapa temprana que, aunque modesta en escala, fortalece la liquidez sin una dilución inmediata de los accionistas debido a comisiones de corretaje.

Scienture Holdings, Inc. (이전 명칭 TRxADE Health/TRXADE Group)는 Reg D 규칙 506(b) 및 증권법 §4(a)(5)에 따라 사모 주식 발행을 보고하기 위해 Form D를 제출했습니다.

  • 공모 규모: 최대 300만 달러; 130만 달러(43%)가 2025년 7월 18일 첫 클로징 이후 판매되었습니다.
  • 투자자: 현재까지 4명의 구매자; 공인 투자자만 명시됨.
  • 증권 종류: 주식; 최소 청약금액 5만 달러.
  • 자금 사용처: 일반 운전자본; 임원/이사에 대한 지급액은 0달러로 책정됨.
  • 공모 비용: 판매 수수료, 중개인 참여 또는 소개 수수료는 공개되지 않음.
  • 발행자 정보: 델라웨어 법인(5년 이상); 본사 뉴욕주 코맥 소재; 산업 분류 제약.
  • 발행자 규모: 매출 및 자산 범위는 “공개 거부”로 표시됨.
  • 기간: 공모는 1년 이내 종료 예정.

이번 제출은 규모는 크지 않지만 중개 수수료로 인한 즉각적인 주주 희석 없이 유동성을 강화하는 초기 단계 자본 조달을 나타냅니다.

Scienture Holdings, Inc. (anciennement TRxADE Health/TRXADE Group) a déposé un Formulaire D pour signaler un placement privé de titres de capitaux propres en vertu de la Règle 506(b) du règlement D et de l'article 4(a)(5) du Securities Act.

  • Taille de l'offre : jusqu'à 3,0 millions de dollars ; 1,3 million de dollars (43 %) ont été vendus depuis la première clôture le 18 juillet 2025.
  • Investisseurs : 4 acheteurs à ce jour ; seuls des investisseurs accrédités sont mentionnés.
  • Titres : actions ; souscription minimale de 50 000 dollars.
  • Utilisation des fonds : fonds de roulement général ; 0 dollar destiné aux paiements aux dirigeants/directeurs.
  • Coûts de l'offre : aucune commission de vente, implication de courtiers ou frais d'intermédiaire divulgués.
  • Détails de l'émetteur : société du Delaware (>5 ans) ; siège principal à Commack, NY ; classification industrielle Pharmaceutique.
  • Taille de l'émetteur : revenus et actifs indiqués comme « Refus de divulguer ».
  • Durée : l'offre devrait se clôturer dans un délai d'un an.

Le dépôt signale une levée de fonds en phase initiale qui, bien que modeste, renforce la liquidité sans dilution immédiate des actionnaires due aux frais de courtage.

Scienture Holdings, Inc. (ehemals TRxADE Health/TRXADE Group) reichte ein Formular D ein, um eine Privatplatzierung von Eigenkapitalwertpapieren gemäß Reg D Regel 506(b) und Securities Act §4(a)(5) zu melden.

  • Angebotsgröße: bis zu 3,0 Millionen US-Dollar; 1,3 Millionen US-Dollar (43 %) wurden seit dem ersten Abschluss am 18. Juli 2025 verkauft.
  • Investoren: Bisher 4 Käufer; nur akkreditierte Investoren angegeben.
  • Wertpapiere: Eigenkapital; Mindestzeichnung 50.000 US-Dollar.
  • Verwendung der Erlöse: allgemeines Betriebskapital; 0 US-Dollar für Zahlungen an leitende Angestellte/Vorstände vorgesehen.
  • Angebotskosten: keine Verkaufsprovisionen, Broker-Dealer-Beteiligung oder Vermittlungsgebühren angegeben.
  • Emittentendetails: Delaware-Gesellschaft (>5 Jahre alt); Hauptsitz in Commack, NY; Branchenklassifikation Pharmazeutika.
  • Emittentengröße: Umsatz- und Vermögensangaben mit dem Hinweis „Keine Angabe“.
  • Dauer: Angebot soll innerhalb eines Jahres abgeschlossen werden.

Die Einreichung signalisiert eine Kapitalaufnahme in einer frühen Phase, die zwar moderat ist, aber die Liquidität stärkt, ohne eine unmittelbare Verwässerung der Aktionäre durch Maklergebühren.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of August 2025
 
 
PEARSON plc
(Exact name of registrant as specified in its charter)
 
N/A
 
(Translation of registrant's name into English)
 
80 Strand
London, England WC2R 0RL
44-20-7010-2000
(Address of principal executive office)
 
 
Indicate by check mark whether the Registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
 
 
 
Form 20-F X                                                Form 40-F
 
 
 
Indicate by check mark whether the Registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
 
 
 
Yes                                              No X
 
 
Pearson Interim Results for the six months to 30th June 2025 (Unaudited)
 
1st August 2025
Continued strategic and operational progress against medium term strategy. On track to deliver 2025 guidance with stronger growth expected in H2.  
 
Financial Highlights
 
£m
H1
2025
vs H1
2024
 
£m
H1
2025
H1
2024
Business performance
Statutory results
Sales
1,722
+2% 1
Sales
1,722
1,754
Adjusted operating profit
242
+2% 1
Operating profit
240
219
Operating cash flow
126
£(3)m
Profit for the period
166
158
Free cash flow
156
+£129m
Net cash generated from operations
188
185
Adjusted earnings per share
24.5p
(4)%2
Basic earnings per share
24.8p
23.1p
 
Highlights
 
Group sales1 up 2% underlying with each business unit performing broadly in line with our expectations.
 
Adjusted operating profit1 up 2% underlying to £242m.
 
Strong free cash performance up £129m to £156m, including the receipt of £114m State Aid tax recovery.
 
Interim dividend up 5% and £350m share buyback well underway, with ongoing balance sheet strength.
 
On track to deliver 2025 guidance with stronger growth expected in H2.
 
Continued strategic and operational progress, including:
 
 
o
Strategic partnerships with Microsoft, AWS, and most recently, Google Cloud, progressing AI transformation agenda (link here);
 
 
o
Enterprise business building momentum, with new partners such as HCLTech (link here);
 
 
o
Continuing to develop product suite and apply innovative technologies including new "Go Deeper" feature within our AI-powered study tools and launch of Pearson English Express Test (link here);
 
 
o
Accelerating access to adjacent markets, with a strategic collaboration with McGraw Hill in formative assessments (link here);
 
 
o
Completed the acquisition of eDynamic Learning, adding a core pillar to our Early Careers strategy (link here).
 
Omar Abbosh, Pearson's Chief Executive, said: 
 
"We are on track to deliver the three priorities we set out for the year, with performance to date in line with our expectations, and are confident of stronger growth in the second half. We are making rapid progress with bringing AI-powered products to market and are scaling and enhancing our enterprise business with a range of new partnerships and deals. Our sharp focus on rigorous execution and continuous innovation is driving progress against our strategy, improving Pearson's agility, efficiency and resilience, and positioning us to deliver consistent mid-single digit sales growth over the medium term."
 
Group sales1 up 2% underlying in H1 2025
 
Assessment & Qualifications sales were up 2% with strong growth in Clinical Assessments and UK & International Qualifications, partially offset by declines in Pearson VUE and US Student Assessment. Pearson VUE decline was driven by the pause in a contract delivered in 2024 which will recommence in H2 2025, and headwinds in PDRI, which has been impacted by US federal government hiring and spend reductions which we expect to continue in the second half.
 
Virtual Learning sales were down 1%, as expected, due to the final portion of the impact of previously announced school losses. 2024/25 academic year enrolments increased 5% in the Spring semester on a same school basis, with favourable retention trends, underpinning our confidence in returning to growth in H2.
 
Higher Education sales were up 4%, benefiting from growth in Inclusive Access of 21% and US digital subscriptions of 3%. We continued to see good monetisation of our Study Prep tool, formerly known as Channels, and ongoing engagement with our AI-powered study tools.
 
English Language Learning sales were down 3%, in line with expectations, with Institutional impacted by a strong comparator period in H1 2024.  Pearson Test of English (PTE) was flat against the prior period, performing well against a tough market backdrop.
 
Enterprise Learning & Skills sales were up 4%, with another solid performance in Vocational Qualifications and Enterprise Solutions building momentum.
 
Adjusted operating profit1 up 2% on an underlying basis to £242m
 
Underlying performance driven by operating leverage on sales growth partially offset by inflation.
 
On a headline basis, profit was down 3% with positive underlying performance more than offset by translation currency headwinds. First half adjusted profit margin was flat against the prior period at 14% (H1 2024: 14%).
 
Adjusted net finance costs increased to £24m (H1 2024: £21m). The effective tax rate on adjusted profit before tax increased to 24.5% (H1 2024: 23.6%).
 
Adjusted earnings per share declined to 24.5p (H1 2024: 25.6p) with positive underlying trading performance, and a reduction in share count due to the share buyback programmes, more than offset by currency headwinds and increased interest.
 
Good cash performance
 
Operating cash flow was in line with the prior period at £126m (H1 2024: £129m) with continued good working capital management offsetting currency headwinds.
 
Free cash flow was again strong up £129m to £156m (H1 2024: £27m) given the operating cash performance and the receipt of £114m State Aid tax recovery, inclusive of interest, in the period.
 
Strong balance sheet supporting continued investment and shareholder returns
 
Net debt decreased £0.2bn to £1.0bn at 30th June 2025 (H1 2024: £1.2bn) as free cash flow was partially offset by dividends and the share buyback.
 
Proposed interim dividend of 7.8p (H1 2024: 7.4p), represents an increase of 5%.
 
Previously announced £350m share buyback programme well underway and is expected to complete in H2. As at 30th June 2025, £169m of shares had been repurchased representing 48% of the total programme.
 
Secured new three-year, $800m revolving credit facility, enhancing our liquidity and strategic flexibility.
 
Statutory results
 
Sales decreased 2% on a headline basis to £1,722m (H1 2024: £1,754m) with currency movements partially offset by positive underlying business performance.
 
Statutory operating profit increased 10% on a headline basis to £240m (H1 2024: £219m) driven by operating leverage on sales growth, gains on disposals and the reversal of impairments on property assets, partially offset by inflation and currency headwinds.
 
Net cash generated from operations of £188m (H1 2024: £185m).
 
Statutory earnings per share of 24.8p (H1 2024: 23.1p).
 
Continued operational and strategic progress
 
Driving performance in the core business
 
In Assessment & Qualifications, Pearson VUE won several new contracts with continued strong customer retention supporting future growth. US Student Assessment also successfully renewed and extended several key contracts in the period. In UK & International Qualifications we continued to scale internationally. In Clinical Assessments we expanded our customer set with our first statewide adoption of our digital offering. The application of AI across our products continued with the launch of an AI-powered GCSE Exam Practice Assistant, as part of our collaboration with AWS.
 
In Virtual Learning, we completed the rollout of our new enrolment portal which we expect to support sales growth in the second half of the year. We are also embedding our career academies across the network ahead of fall back to school and are on track to open two new schools in H2 taking our total number of schools up to 42. We also successfully secured all six of our long term school contracts being renewed in H1. We continue to apply innovative technologies through integrating AI into our study tools, driving higher course scores and end-of-semester pass rates.
 
In Higher Education, we continued to build upon the successful monetisation of our Study Prep tool which we expanded into international markets in the first half of this year. We continue to rollout our AI-powered study tools across disciplines - including our new "Go Deeper" feature, which further supports students with engagement, new cognitive skills and higher order learning outcomes.
 
In English Language Learning, we announced a partnership with BorderPass, expanding our PTE go-to-market reach for international students and skilled migrants in Canada. We are also launching our new Pearson English Express Test which expands our addressable market, responding to demand for a trusted, accessible test for US-bound learners. Within Institutional we continue to expand internationally with customer wins in LATAM. We continue to make progress on the application of innovative technologies with the recent launch of AI-powered Smart Lesson Generator and Digital Language Tutor.
 
In Enterprise Learning & Skills, Vocational Qualifications delivered a solid performance in the period with several new contract wins supporting pipeline growth, including apprenticeship courses with the UK Ministry of Defence, T Levels in Health and Science, and International BTEC expansion. Within Enterprise Solutions we announced strategic partnerships with Microsoft, AWS and Google Cloud and are building momentum in our Enterprise approach, with new partners such as HCLTech.  We have made enhancements to our talent assessment platform, TalentLens, through combining capabilities with PDRI's secure and scalable Palladium offering. We have also enabled third party credential uploads onto the Credly platform, to advance our goal of Credly becoming the most complete source of verified learning and skills data globally.
 
Progress in unlocking faster growth adjacent market opportunities
 
Higher Education recently completed the acquisition of eDynamic Learning, a leading Career and Technical Education (CTE) curriculum solutions provider for an enterprise value of $225m, enabling us to broaden capabilities and scale our position in the fast-growing Early Careers space.
 
We have operationalised our dedicated K-12 sales team within Higher Education, enabling us to expand and strengthen customer relationships with US school administrators as the demand for college and career readiness programmes grows.
 
Pearson VUE successfully launched the Pearson Skilling Suite and continues to make progress building out its test prep business.
 
Within US Student Assessment we announced an exclusive partnership with McGraw Hill to integrate our leading interim assessment capabilities directly into McGraw Hill's K-12 curriculum solutions, unlocking go-to-market opportunities in formative assessment.

Outlook
 
Reaffirm 2025 guidance
 
We continue to expect sales growth and adjusted operating profit in line with market expectations4 for 2025 with stronger sales growth in H2, in particular in Q4. We outline our 2025 guidance later in this release.
 
The acquisition of eDynamic Learning is not expected to have a material impact to 2025 guidance given near term integration costs and the acquisition accounting for deferred revenue.
 
Medium term outlook
 
Beyond 2025, Pearson is positioned to deliver a mid-single digit underlying sales growth CAGR, sustained margin improvement that will equate to an average increase of 40 basis points per annum and strong free cash conversion5, in the region of 90% to 100%, on average, across the period.
 
Contacts
 
Investor Relations
Alex Shore
Steph Crinnegan
 +44 (0) 7720 947 853
 +44 (0) 7780 555 351
 
Gemma Terry
Brennan Matthews
 +44 (0) 7841 363 216
 +1 (332) 238-8785
Media
Teneo
Pearson
 
Ed Cropley
Laura Ewart
 
 +44 (0) 7492 949 346
 +44 (0) 7798 846 805
Results event
Pearson's Interim Results presentation will be held today at 08:30 (BST). Register to join session virtually (link here).
 
 
About Pearson
 
At Pearson, our purpose is simple: to help people realise the life they imagine through learning. We believe that every learning opportunity is a chance for a personal breakthrough. That's why our Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world's lifelong learning company, serving customers with digital content, assessments, qualifications, and data. For us, learning isn't just what we do. It's who we are. Visit us at pearsonplc.com.
 
Notes
 
Forward looking statements: Except for the historical information contained herein, the matters discussed in this statement include forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing, anticipated cost savings and synergies and the execution of Pearson's strategy, are forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that will occur in future. They are based on numerous assumptions regarding Pearson's present and future business strategies and the environment in which it will operate in the future. There are a number of factors which could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including a number of factors outside Pearson's control. These include international, national and local conditions, as well as competition. They also include other risks detailed from time to time in Pearson's publicly-filed documents and you are advised to read, in particular, the risk factors set out in Pearson's latest annual report and accounts, which can be found on its website (www.pearsonplc.com). Any forward-looking statements speak only as of the date they are made, and Pearson gives no undertaking to update forward-looking statements to reflect any changes in its expectations with regard thereto or any changes to events, conditions or circumstances on which any such statement is based. Readers are cautioned not to place undue reliance on such forward-looking statements.

Operational review
 
 
£m
 
H1 2025
 
H1 20243
Headline
growth
Underlying
growth1
Sales
Assessment & Qualifications
802
811
(1)%
2%
Virtual Learning
242
254
(5)%
(1)%
Higher Education
337
336
0%
4%
English Language Learning
171
188
(9)%
(3)%
Enterprise Learning & Skills
170
165
3%
4%
Total
1,722
1,754
(2)%
2%
 
 
 
 
 
Adjusted operating profit/(loss)
Assessment & Qualifications
170
187
(9)%
(6)%
Virtual Learning
39
31
26%
32%
Higher Education
(3)
(7)
57%
75%
English Language Learning
(7)
4
(275)%
(200)%
Enterprise Learning & Skills
43
35
23%
20%
Total
242
250
(3)%
2%
 
1Throughout this announcement: a) Growth rates are stated on an underlying basis unless otherwise stated. Underlying growth rates exclude currency movements, and portfolio changes. b) The 'business performance' measures are non-GAAP measures and reconciliations to the equivalent statutory heading under IFRS are included in notes to the attached condensed consolidated financial statements 2, 3, 4, 6 and 12.
2 Headline growth rate.
3In January 2025, the Group announced that Workforce Skills would evolve to become Enterprise Learning & Skills, incorporating our IT Pro business which was previously in Higher Education. Comparative figures have been restated to reflect the move between segments, resulting in £22m of sales and £6m of adjusted operating profit being transferred from Higher Education to Enterprise Learning & Skills for the six months ended 30 June 2024. The full year 2024 impact is £45m of sales and £12m of adjusted operating profit.

Assessment & Qualifications
 
In Assessment & Qualifications, sales increased 2% on an underlying basis and declined 1% on a headline basis due to currency movements offsetting trading. Adjusted operating profit decreased 6% in underlying terms due to operating leverage on sales growth more than offset by cost phasing, and 9% in headline terms due to this and currency movements.
 
Pearson VUE sales declined 3% on an underlying basis driven by the pause in a contract delivered in 2024 which will recommence in H2 2025, and headwinds in PDRI, which has been impacted by US federal government hiring and spend reductions which we expect to continue in the second half.
 
In US Student Assessment, sales decreased 1% in underlying terms due to changes in timing of delivery.
 
In Clinical Assessment, sales increased 11% in underlying terms due to the continued traction of our products in the market, pricing and digital product growth.
 
In UK and International Qualifications, sales increased 10% in underlying terms driven by volume, pricing and strong International growth.
 
Virtual Learning
 
Virtual Learning sales were down 1% on an underlying basis, as expected, due to the final portion of the impact of previously announced school losses. On a headline basis sales were down 5% due to this and currency movements. 2024/25 academic year enrolments increased 5% in the Spring semester on a same school basis and grew 7% including new school openings. We have also seen favorable retention trends in H1. Adjusted operating profit increased 32% in underlying terms driven by cost savings and phasing partially offset by trading, and increased 26% in headline terms due to this and currency movements.
 
Higher Education
 
In Higher Education, sales increased 4% on an underlying basis, benefitting from growth in Inclusive Access of 21% and US digital subscriptions of 3%. We continued to see good monetisation of our Study Prep tool and ongoing engagement with our AI study tools. Sales were flat on a headline basis as underlying growth was offset by currency movements. Adjusted operating profit increased in underlying terms driven by operating leverage on sales growth, with the headline result also reflecting currency movements.
 
English Language Learning
 
In English Language Learning, sales were down 3% on an underlying basis, in line with expectations, with our Institutional business performing well in Q2 but impacted by a strong comparator period in H1 last year. PTE sales were flat, performing well against a tough market backdrop, with volumes decreasing 10%. Sales were down 9% on a headline basis due to this and currency movements. Adjusted operating profit decreased due to the decline in trading and decreased in headline terms due to this and currency movements.
 
Enterprise Learning & Skills
 
In Enterprise Learning & Skills, sales were up 4% on an underlying basis and 3% on a headline basis. Adjusted operating profit increased by 20% in underlying terms due to operating leverage on sales and increased 23% in headline terms due to this and currency movements.
 
Vocational Qualifications delivered solid growth while Enterprise Solutions improved quarter on quarter as we build momentum in our Enterprise approach and related sales capability, including new wins such as HCLTech.

2025 guidance summary
 
Underlying Sales growth
Group
In line with market expectations4 with stronger sales growth in H2, in particular in Q4.
 
Assessment & Qualifications
Sales to grow low to mid-single digit. Growth will be H2 weighed, in particular to Q4, due to new and renewed contracts and the new test prep business.
 
Virtual Learning
Return to growth in H2, and for the full year, driven by enrolment increases, partially from new school openings, for the 25/26 academic year.
 
Higher Education
Sales growth in 2025 will be higher than in 2024 as we build on the successful results of our sales team transformation and product innovations, particularly using AI.
 
English Language Learning
Sales growth will moderate given the impacts of elections on immigration rates in 2025 affecting our PTE business, which is expected to decline in the year. We expect growth to be H2 weighted, in particular to Q4. We remain confident in the medium term outlook given demographic projections.  
 
Enterprise Learning & Skills
Sales to grow high single digit with Vocational Qualifications seeing solid growth and the addition of several new contracts for Enterprise Solutions. Growth will increase quarter on quarter supported by recent customer annoucements and pipeline activity.
 
Group Profit
Adjusted Operating Profit
In line with market expectations4.
 
Interest
Adjusted net finance costs of c.£65m.
 
Tax rate
We expect the effective tax rate on adjusted profit before tax to be between 24% and 25%.
 
Cash flow
We expect a free cash flow conversion5 of 90-100% plus the £0.1bn State Aid repayment which was received in full during Q1 2025.
 
FX
Every 1c movement in GBP:USD rate equates to approximately £5m adjusted operating profit impact.
 
 
42025 consensus on the Pearson website dated 27th January 2025; underlying sales growth 4.4%, adjusted operating profit of £656m at £:$ 1.23.  Taking the average FX rate for H1 2025 (£:$1.31) and assuming the July 2025 month end rate of (£:$1.32) for the rest of the year, results in an implied FX rate for the full year of £:$1.32. This results in an updated adjusted operating profit of c.£611m.   
5Free cash flow conversion calculated as free cash flow divided by adjusted earnings.
 
Exchange rates
H1 2025
H1 2024
FY 2024
£:$
 
 
 
Average rate for profits
1.31
1.26
1.28
Period end rate
1.37
1.26
1.25
 
FINANCIAL REVIEW
 
Operating result
 
Sales for the six months to 30 June 2025 decreased on a headline basis by £32m or 2% from £1,754m for the six months to 30 June 2024 to £1,722m for the same period in 2025 and adjusted operating profit decreased by 3% on a headline basis to £242m in the first half of 2025 compared to £250m in the first half of 2024 (for a reconciliation of this measure see note 2 to the condensed consolidated financial statements).
 
The headline basis simply compares the reported results for the six months to 30 June 2025 with those for the equivalent period in the prior year. We also present sales and profits on an underlying basis which excludes the effects of exchange, the effect of portfolio changes arising from acquisitions and disposals and the impact of adopting new accounting standards that are not retrospectively applied, when relevant. Our portfolio change is calculated by excluding sales and profits made by businesses disposed in 2024 or 2025 and by ensuring the contribution from acquisitions is comparable year on year. For prior year acquisitions, the corresponding pre-acquisition period is excluded from the current year. Portfolio changes mainly relate to the disposal of Copp Clark in 2025.
 
On an underlying basis, sales increased by 2% in the first six months of 2025 compared to the equivalent period in 2024 and adjusted operating profit increased by 2%. Currency movements decreased sales by £58m and adjusted operating profit by £11m, and portfolio changes had no impact on sales and decreased adjusted operating profit by £1m. There were no new accounting standards adopted in the first half of 2025 that impacted sales or profits.
 
Adjusted operating profit includes the results from discontinued operations when relevant but excludes charges for acquired intangible amortisation and impairment, acquisition related costs, gains and losses arising from disposals, the cost of major reorganisation, when relevant, property charges and one off-costs related to the UK pension scheme. A summary of these adjustments is included below and in note 2 to the condensed consolidated financial statements.
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Operating profit
 
240
219
541
Add back: Cost of major reorganisation
 
-
-
(2)
Add back: Intangible charges
 
20
20
41
Add back: UK pension discretionary increase
 
-
5
13
Add back: Other net gains and losses
 
(7)
6
7
Add back: Property charges
 
(11)
-
-
Adjusted operating profit
 
242
250
600
 
Costs of major reorganisation - In the first half of 2025 and 2024, there were no costs of major reorganisation. In the second half of 2024, there was a release of £2m relating to amounts previously accrued.
 
Intangible amortisation charges to the end of June 2025 were £20m compared to a charge of £20m in the equivalent period in 2024.
 
UK pension discretionary increases in 2024 relate to one-off pension increases awarded to certain cohorts of pensioners in response to the cost of living crisis. There were no such amounts in 2025.
 
Other net gains and losses in 2025 relate to the gain on disposal of a business in our Higher Education division, a fair value gain relating to a previous disposal and costs relating to prior year acquisitions and disposals. Other net gains and losses in 2024 relate to costs related to prior year acquisitions and disposals, partially offset by a gain on the partial disposal of our investment in an associate.
 
Property charges in 2025 are a gain of £11m, relating to reversals of impairments of property assets that were previously impaired through property charges. There are no such amounts in 2024.
 
The reported operating profit of £240m in the first half of 2025 compares to a profit of £219m in the first half of 2024. The increase has been driven by operating leverage on sales growth, gains on disposals and the reversal of impairments on property assets, partially  offset by inflation and unfavourable foreign exchange movements.
 
Due to seasonal bias in some of the Group's businesses, Pearson typically makes a higher proportion of its profits and operating cash flows in the second half of the year.
 
Net finance costs
 
Net finance costs increased on a headline basis from a net cost of £7m in the first half of 2024 to a net cost of £22m in the same period in 2025. The increase is primarily due to increased borrowing costs as a result of the bond issued in September 2024 and losses on derivatives held at fair value through profit and loss (FVTPL) compared to gains in 2024, offset by reduced fees related to drawings on the revolving credit facility and an increase in returns on cash deposits.
 
Adjusted net finance costs reflected in adjusted earnings to 30 June 2025 was £24m, compared to a net cost of £21m in the first half of 2024. The increase is primarily due to increased borrowing costs as a result of the bond issued in September 2024, offset by reduced fees related to drawings on the revolving credit facility and an increase in returns on cash deposits.
 
In the period to 30 June 2025, the total of items excluded from adjusted earnings was net income of £2m compared to net income of £14m in the first half of 2024. For a reconciliation of the adjusted measure see note 3 to the condensed consolidated financial statements.
 
Taxation
 
The reported tax on statutory earnings for the six months to 30 June 2025 was a charge of £52m compared to a charge of £54m in the period to 30 June 2024. This equates to an effective tax rate of 23.9% (2024: 25.5%), with the reduction from prior year principally being due to an impairment reversal which is not taxable.
 
The total adjusted tax charge for the period was £54m (2024: £54m), corresponding to an effective tax rate on adjusted profit before tax of 24.5% (2024: 23.6%). For a reconciliation of the adjusted measure see note 4 to the condensed consolidated financial statements.
 
In the first half of 2025, there was a net tax receipt of £35m (2024: £69m net tax payment). This includes a £97m repayment from HMRC in respect of the State Aid matter, with an additional £17m of associated interest also received in the period, classified within interest received in the cash flow statement. This repayment is a result of the Court of Justice of the European Union ('CJEU') handing down its decision on 19 September 2024 determining that the United Kingdom controlled foreign company group financing partial exemption ('FCPE') did not constitute State Aid, thereby resulting in a refund of the £97m of tax paid (plus £17m of interest) under the Charging Notices issued by HMRC in 2021. The balance excluding the State Aid repayment, principally relates to tax payments in the US and the UK.
 
Other comprehensive income
 
Included in other comprehensive income are the net exchange differences on translation of foreign operations. The loss on translation of £263m at 30 June 2025 compares to a loss at 30 June 2024 of £9m. The loss in 2025 arises from an overall weakening of the majority of currencies to which the Group is exposed, in particular the US dollar. A significant proportion of the Group's operations are based in the US and the US dollar closing rate at 30 June 2025 was £1:$1.37 compared to the opening rate of £1:$1.25. At the end of June 2024, the US dollar rate was £1:$1.26 compared to the opening rate of £1:$1.27.
 
Also included in other comprehensive income at 30 June 2025 is an actuarial loss of £12m in relation to retirement benefit obligations. The loss arises largely from losses on assets and experience losses, offset by a decrease in liabilities driven by lower long-term inflation rates. The loss in 2025 compares to an actuarial gain at 30 June 2024 of £1m.
 
Fair value losses of £6m (2024: losses of £4m) have been recognised in other comprehensive income and relate to movements in the value of investments in unlisted securities held at fair value through other comprehensive income (FVOCI).
 
Cash flow and working capital
 
Our operating cash flow measure is used to align cash flows with our adjusted profit measures (see note 12 to the condensed consolidated financial statements). Operating cash flow decreased on a headline basis by £3m from an inflow of £129m in the first half of 2024 to an inflow of £126m in the first half of 2025. The decrease is largely explained by good working capital management offset by unfavourable FX movements. 
 
The equivalent statutory measure, net cash generated from operations, was an inflow of £188m in 2025 compared to an inflow of £185m in 2024. Compared to operating cash flow, this measure includes reorganisation costs but does not include regular dividends from associates. It also excludes capital expenditure on property, plant, equipment and software, and additions to right of use assets as well as disposal proceeds from the sale of property, plant, equipment and right of use assets (including the impacts of transfers to/from investment in finance lease receivable). In the first half of 2025, reorganisation cash outflow was £nil compared to £5m in the same period in 2024.
 
Free cash flow increased on a headline basis by £129m from £27m in 2024 to £156m in 2025. When compared to operating cash flow, free cash flow includes tax paid/received, net finance costs paid and net costs paid for major reorganisation. The increase year on year is mainly due to the receipt of monies in respect of the State Aid tax matter.
 
In the first half of 2025, there was an overall decrease of £196m in cash and cash equivalents from £543m at the end of 2024 to £347m at 30 June 2025. The decrease in 2025 is primarily due to the cash inflow from operations of £188m, net tax received of £35m and net proceeds from borrowings of £46m, offset by dividends paid of £110m, share buyback programme payments of £158m, own share purchases of £72m, capital expenditure on property, plant, equipment and software of £62m and payments of lease liabilities of £38m.
 
Liquidity and capital resources
 
The Group's net debt increased from £853m at the end of 2024 to £1,027m at the end of June 2025. The increase is largely due to free cash flow of £156m including the State Aid repayment which are more than offset by the share buyback programme, other own share purchases and dividend payments. In May 2025, the Group repaid its €300m bond and closed out various related derivatives. In June 2025, the Group secured a new three-year, $800 million revolving credit facility (RCF). This facility can be utilised for general corporate purposes, enhancing our liquidity, and is in addition to the Group's existing RCF. At 30 June 2025, the Group had drawn £300m on its Revolving Credit Facilities.
 
At 30 June 2025, the Group had approximately £1.2bn in total liquidity immediately available from cash and its RCFs maturing February and June 2028. In assessing the Group's ability to continue as a going concern for the period until 31 December 2026, the Board analysed a variety of downside scenarios, including a severe but plausible scenario, where the Group is impacted by a combination of all principal risks from H2 2025, as well as reverse stress testing to identify what would be required to either breach covenants or run out of liquidity. The severe but plausible scenario modelled a severe reduction in revenue, profit and operating cash flow from risks continuing throughout 2026. In all scenarios, the Group would maintain comfortable liquidity headroom and sufficient headroom against covenant requirements during the period under assessment even before modelling the mitigating effect of actions that management would take in the event that these downside risks were to crystallise. The directors concluded that the likelihood of the reverse stress test scenario was remote.
 
Post-retirement benefits
 
Pearson operates a variety of pension and post-retirement plans. The UK Group pension plan has by far the largest defined benefit section. This plan has a strong funding position and a surplus with a very substantially de-risked investment portfolio including approximately 50% of the assets in buy-in contracts. We have some smaller defined benefit sections in the US and Canada but, outside the UK, most of the companies operate defined contribution plans.
 
The charge to profit in respect of worldwide pensions and retirement benefits amounted to £21m in the period to 30 June 2025 (30 June 2024: £30m) of which a charge of £33m (30 June 2024: £41m) was reported in operating profit and income of £12m (30 June 2024: £11m) was reported against other net finance costs. In the period to 30 June 2024, a charge of £5m related to one-off discretionary pension increases was excluded from adjusted operating profit, with no such amounts in 2025.
 
The overall surplus on UK Group pension plans of £484m at the end of 2024 has decreased to a surplus of £482m at the end of June 2025. The decrease has arisen principally due to asset returns being lower than expected and inflation over the period being slightly higher than was expected at the beginning of the year. In total, our worldwide net position in respect of pensions and other post-retirement benefits increased from a net asset of £450m at the end of 2024 to a net asset of £453m at the end of June 2025.
 
Businesses acquired and disposed
 
The Group made no acquisitions of subsidiaries in the first half of 2025 or 2024. The cash outflow in the first half of 2025 relating to acquisition of subsidiaries was £4m arising from the payment of deferred consideration in respect of prior year acquisitions. The cash outflow in the first half of 2024 relating to acquisitions of subsidiaries was £38m, arising from the payment of deferred consideration in respect of prior year acquisitions, mainly Credly and Mondly, which were acquired in 2022. In addition, there was a cash outflow relating to investments of £5m (2024: £7m).
 
The Group disposed of Copp Clark in the first half of 2025 for consideration of £9m, resulting in a gain on disposal of £8m, which has been recorded within other net gains and losses. There were no disposals of subsidiaries in the first half of 2024. In 2025, the cash inflow relating to the disposal of businesses was £9m (2024: outflow of £6m).
 
On 24 July 2025, the Group completed the acquisition of 100% of eDynamic Holdings LP ('eDynamic Learning'), a leading Career and Technical Education (CTE) curriculum solutions provider, having obtained all necessary approvals. Since the acquisition closed subsequent to the half year date, it has not been reflected in the interim financial statements. For further details, see note 15 to the condensed consolidated financial statements.
 
Dividends
 
The dividend accounted for in the six months to 30 June 2025 is the final dividend in respect of 2024 of 16.6p. An interim dividend for 2025 of 7.8p was declared by the Board in July 2025 and will be accounted for in the second half of 2025. The interim dividend will be paid on 15 September 2025 to shareholders who are on the register of members at close of business on 15 August 2025 (the Record Date). Shareholders may elect to reinvest their dividend in the Dividend Reinvestment Plan (DRIP). The last date for receipt of DRIP elections and revocations will be 22 August 2025. A Dividend Reinvestment Plan (DRIP) is provided by our Registrar, Computershare Investor Services. The DRIP enables the Company's shareholders to elect to have their cash dividend payments used to purchase the Company's shares. More information can be found at www.computershare.com/Investor
 
Share buyback
 
On 27 February 2025, the Board approved a £350m share buyback programme in order to return capital to shareholders. In the first half of 2025, c15m shares have been bought back at a cash cost of £158m. A £18m liability for the remainder of the first tranche of the programme plus related costs has been accrued as at 30 June 2025. The nominal value of the cancelled shares of £3m has been transferred to the capital redemption reserve. In the period from 1 to 30 July 2025, an additional c4m of shares have been repurchased.
 
Principal risks and uncertainties
 
In the 2024 Annual Report and Accounts, we set out our assessment of the principal risk issues that face the business under the categories: accreditation risk, artificial intelligence, content and channel risks, capability risk, competitive marketplace, customer expectations, portfolio change, and reputation and responsibility. We also noted in our 2024 Annual Report and Accounts that the Group continues to closely monitor significant near-term and emerging risks which have been identified as climate transition, economic changes, tax, sanctions and geopolitics.
 
The principal risks and uncertainties are summarised below. The selection of principal risks will be reviewed in the second half of the year alongside the Group's long-term strategic planning process. However, these risks have not changed materially from those detailed in the 2024 Annual Report.
 
Accreditation Risk
 
Termination or modification of accreditation due to policy changes or failure to maintain the accreditation of our courses and assessments by states, countries, and professional associations, reducing their eligibility for funding or attractiveness to learners. Awarding bodies may also require modification of tests to continue to receive accreditation which may reduce the convenience to learners or increase the cost of delivery.
 
Artificial Intelligence, Content and Channel Risk
 
The risk that our intellectual property is harder to protect as a result of increased content generation through artificial intelligence and that our content and method of delivery (channel) is, or is perceived to be, insufficiently differentiated in terms of outcomes or learner experience. 
 
Capability Risk
 
Inability to meet our contractual obligations or to transform as required by our strategy, due to infrastructure, systems or organisational challenges.
 
Competitive Marketplace
 
Significant changes in our target markets could make those markets less attractive. This could be due to significant changes in demand or in supply, which impact the addressable market, market share and margins (e.g. changes in enrolments, in-sourcing of learning and assessment by customers, open educational resources, a shift from in-person to virtual learning or vice versa, or innovations in areas such as generative AI).
 
Customer Expectations
 
Rising end-user expectations increase the need to offer differentiated value propositions, risking margin pressure to meet these expectations and potential loss of sales if not successful.
 
Portfolio Change
 
Failure to effectively execute desired or required portfolio changes to promote scale or capability and increase focus on key business units and geographic markets, due to either execution failures or inability to secure transactions at appropriate valuations.
 
Reputation and Responsibility
 
Reputational and responsibility risks involve failing to meet obligations and demands of key stakeholders, including legal, regulatory, ethical and behavioural expectations. These risks extend beyond direct consequences to include broader societal and cultural perceptions.
 
CONDENSED CONSOLIDATED INCOME STATEMENT
for the period ended 30 June 2025
 
 
 
 
 
 
all figures in £ millions
note
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Continuing operations
 
 
 
 
 
 
 
 
 
Sales
2
1,722
1,754
3,552
Cost of goods sold
 
(843)
(875)
(1,741)
Gross profit
 
879
879
1,811
 
 
 
 
 
Operating expenses
 
(645)
(654)
(1,265)
Other net gains and losses
2
7
(6)
(7)
Share of results of joint ventures and associates
 
(1)
-
2
Operating profit
2
240
219
541
 
 
 
 
 
Finance costs
3
(47)
(57)
(112)
Finance income
3
25
50
81
Profit before tax
 
218
212
510
Income tax
4
(52)
(54)
(75)
Profit for the period
 
166
158
435
 
 
 
 
 
Attributable to:
 
 
 
 
Equity holders of the company
 
164
157
434
Non-controlling interest
 
2
1
1
 
 
 
 
 
Earnings per share from continuing operations (in pence per share)
 
 
 
 
   Basic
5
24.8p
23.1p
64.5p
   Diluted
5
24.5p
22.8p
63.5p
 
 
 
 
 
 
The accompanying notes to the condensed consolidated financial statements form an integral part of the financial information.
 
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the period ended 30 June 2025
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Profit for the period
 
166
158
435
 
 
 
 
 
Items that may be reclassified to the income statement
 
 
 
 
Net exchange differences on translation of foreign operations
 
(263)
(9)
(35)
Attributable tax
 
(1)
-
2
 
 
 
 
 
Items that are not reclassified to the income statement
 
 
 
 
Fair value loss on other financial assets
 
(6)
(4)
(2)
Attributable tax
 
-
-
-
 
 
 
 
 
Remeasurement of retirement benefit obligations
 
(12)
1
5
Attributable tax
 
3
-
(2)
Other comprehensive expense
 
(279)
(12)
(32)
Total comprehensive (expense) / income
 
(113)
146
403
 
 
 
 
 
 
 
 
 
 
Attributable to:
 
 
 
 
Equity holders of the company
 
(114)
145
402
Non-controlling interest
 
1
1
1
 
CONDENSED CONSOLIDATED BALANCE SHEET
as at 30 June 2025
 
 
 
 
 
 
all figures in £ millions
note
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Property, plant and equipment
 
203
207
216
Investment property
 
74
75
77
Intangible assets
9
2,809
3,050
3,026
Investments in joint ventures and associates
 
11
11
12
Deferred income tax assets
 
48
34
52
Financial assets - derivative financial instruments
 
16
4
20
Retirement benefit assets
 
488
491
491
Other financial assets
 
126
141
141
Income tax assets
 
-
41
4
Trade and other receivables
 
108
134
125
Non-current assets
 
3,883
4,188
4,164
 
 
 
 
 
Intangible assets - product development
 
873
941
947
Inventories
 
71
89
74
Trade and other receivables
 
999
1,081
1,030
Financial assets - derivative financial instruments
 
38
55
31
Current income tax assets
 
14
23
103
Cash and cash equivalents (excluding overdrafts)
 
347
332
543
Current assets
 
2,342
2,521
2,728
 
 
 
 
 
Assets classified as held for sale
 
-
-
-
Total assets
 
6,225
6,709
6,892
 
 
 
 
 
Financial liabilities - borrowings
10
(1,426)
(1,300)
(1,157)
Financial liabilities - derivative financial instruments
 
(3)
(3)
(4)
Deferred income tax liabilities
 
(68)
(56)
(63)
Retirement benefit obligations
 
(35)
(42)
(41)
Provisions for other liabilities and charges
 
(11)
(14)
(13)
Other liabilities
 
(64)
(65)
(83)
Non-current liabilities
 
(1,607)
(1,480)
(1,361)
 
 
 
 
 
Trade and other liabilities
 
(902)
(1,036)
(1,054)
Financial liabilities - borrowings
10
(62)
(313)
(315)
Financial liabilities - derivative financial instruments
 
(11)
(44)
(54)
Current income tax liabilities
 
(13)
(15)
(32)
Provisions for other liabilities and charges
 
(25)
(10)
(23)
Current liabilities
 
(1,013)
(1,418)
(1,478)
 
 
 
 
 
Liabilities classified as held for sale
 
-
-
-
Total liabilities
 
(2,620)
(2,898)
(2,839)
 
 
 
 
 
Net assets
 
3,605
3,811
4,053
 
 
 
 
 
Share capital
 
163
167
166
Share premium
 
2,652
2,644
2,649
Treasury shares
 
(22)
(15)
(7)
Reserves
 
796
1,000
1,230
Total equity attributable to equity holders of the company
 
3,589
3,796
4,038
Non-controlling interest
 
16
15
15
Total equity
 
3,605
3,811
4,053
 
The condensed consolidated financial statements were approved by the Board on 31 July 2025.
 
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the period ended 30 June 2025
 
 
 
 
 
 
Equity attributable to equity holders of the company
 
 

Share capital
Share premium
Treasury shares
Capital redemption reserve
Fair value reserve
Translation reserve
Retained earnings
Total
Non-controlling interest
Total equity
all figures in £ millions
 
 
 
 
 
 
 
 
 
 
2025 half year
 
At 1 January 2025
166
2,649
(7)
41
(14)
376
827
4,038
15
4,053
Profit for the period
-
-
-
-
-
-
164
164
2
166
Other comprehensive income / (expense)
-
-
-
-
(6)
(262)
(10)
(278)
(1)
(279)
Total comprehensive income / (expense)
-
-
-
-
(6)
(262)
154
(114)
1
(113)
Equity-settled transactions1
-
-
-
-
-
-
14
14
-
14
Issue of ordinary shares
-
3
-
-
-
-
-
3
-
3
Buyback of equity
(3)
-
-
3
-
-
(178)
(178)
-
(178)
Purchase of treasury shares
-
-
(64)
-
-
-
-
(64)
-
(64)
Release of treasury shares
-
-
49
-
-
-
(49)
-
-
-
Dividends
-
-
-
-
-
-
(110)
(110)
-
(110)
At 30 June 2025
163
2,652
(22)
44
(20)
114
658
3,589
16
3,605
 
 
 
 
 
 
 
 
 
 
 
 
 
1.   Equity-settled transactions are presented net of withholding taxes that the Group is obligated to pay on behalf of employees. The payments to the tax authorities are accounted for as a deduction from equity for the shares withheld.
 
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the period ended 30 June 2025
 
 
 
 
 
 
Equity attributable to equity holders of the company
 
 

Share capital
Share premium
Treasury shares
Capital redemption reserve
Fair value reserve
Translation reserve
Retained earnings
Total
Non-controlling interest
Total equity
all figures in £ millions
 
 
 
 
 
 
 
 
 
 
2024 half year
At 1 January 2024
174
2,642
(19)
33
(12)
411
745
3,974
14
3,988
Profit for the period
-
-
-
-
-
-
157
157
1
158
Other comprehensive income / (expense)
-
-
-
-
(4)
(9)
1
(12)
-
(12)
Total comprehensive income / (expense)
-
-
-
-
(4)
(9)
158
145
1
146
Equity-settled transactions1
-
-
-
-
-
-
16
16
-
16
Issue of ordinary shares
-
2
-
-
-
-
-
2
-
2
Buyback of equity
(7)
-
-
7
-
-
(204)
(204)
-
(204)
Purchase of treasury shares
-
-
(30)
-
-
-
-
(30)
-
(30)
Release of treasury shares
-
-
34
-
-
-
(34)
-
-
-
Dividends
-
-
-
-
-
-
(107)
(107)
-
(107)
At 30 June 2024
167
2,644
(15)
40
(16)
402
574
3,796
15
3,811
 
1.     Equity-settled transactions are presented net of withholding taxes that the Group is obligated to pay on behalf of employees. The payments to the tax authorities are accounted for as a deduction from equity for the shares withheld.
 
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the period ended 30 June 2025
 
 
 
 
 
 
Equity attributable to equity holders of the company
 
 

Share capital
Share premium
Treasury shares
Capital redemption reserve
Fair value reserve
Translation reserve
Retained earnings
Total
Non-controlling interest
Total equity
all figures in £ millions  
 
 
 
 
 
 
 
 
 
 
2024 full year
At 1 January 2024
174
2,642
(19)
33
(12)
411
745
3,974
14
3,988
Profit for the period
-
-
-
-
-
-
434
434
1
435
Other comprehensive income / (expense)
-
-
-
-
(2)
(35)
5
(32)
-
(32)
Total comprehensive income / (expense)
-
-
-
-
(2)
(35)
439
402
1
403
Equity-settled transactions1
-
-
-
-
-
-
37
37
-
37
Tax on equity-settled transactions
-
-
-
-
-
-
11
11
-
11
Issue of ordinary shares
-
7
-
-
-
-
-
7
-
7
Buyback of equity
(8)
-
-
8
-
-
(204)
(204)
-
(204)
Purchase of treasury shares
-
-
(33)
-
-
-
-
(33)
-
(33)
Release of treasury shares
-
-
45
-
-
-
(45)
-
-
-
Dividends
-
-
-
-
-
-
(156)
(156)
-
(156)
At 31 December 2024
166
2,649
(7)
41
(14)
376
827
4,038
15
4,053
 
1.     Equity-settled transactions are presented net of withholding taxes that the Group is obligated to pay on behalf of employees. The payments to the tax authorities are accounted for as a deduction from equity for the shares withheld.

CONDENSED CONSOLIDATED CASH FLOW STATEMENT
for the period ended 30 June 2025
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Cash flows from operating activities
 
 
 
 
Profit before tax
 
218
212
510
Net finance costs
 
22
7
31
Depreciation and impairment - PPE, investment property and assets held for sale
 
28
40
77
Amortisation and impairment - software
 
57
61
117
Amortisation and impairment - acquired intangible assets
 
20
20
41
Other net gains and losses
 
(7)
5
5
Product development capital expenditure
 
(125)
(130)
(284)
Product development amortisation
 
139
144
291
Share-based payment costs
 
22
23
44
Change in inventories
 
(1)
1
15
Change in trade and other receivables
 
(37)
(34)
32
Change in trade and other liabilities
 
(122)
(164)
(99)
Change in provisions for other liabilities and charges
 
2
(12)
(1)
Other movements
 
(28)
12
32
Net cash generated from operations
 
188
185
811
Interest paid
 
(31)
(41)
(65)
Tax received / (paid)
 
35
(69)
(119)
Net cash generated from operating activities
 
192
75
627
Cash flows from investing activities
 
 
 
 
Acquisition of subsidiaries, net of cash acquired
 
(4)
(38)
(39)
Purchase of investments
 
(5)
(7)
(7)
Purchase of property, plant and equipment
 
(14)
(18)
(33)
Purchase of intangible assets
 
(48)
(40)
(91)
Disposal of subsidiaries, net of cash disposed
 
9
(6)
(7)
Proceeds from sale of property, plant and equipment
 
3
6
6
Lease receivables repaid including disposals
 
9
9
18
Interest received
 
26
13
20
Dividends received
 
-
-
2
Net cash used in investing activities
 
(24)
(81)
(131)
Cash flows from financing activities
 
 
 
 
Proceeds from issue of ordinary shares
 
3
2
7
Buyback of equity
 
(158)
(278)
(318)
Settlement of share based payments
 
(72)
(37)
(40)
Repayment of borrowings
 
(304)
-
(921)
Proceeds from borrowings
 
350
495
1,265
Repayment of lease liabilities
 
(38)
(39)
(78)
Dividends paid to company's shareholders
 
(110)
(107)
(156)
Net cash (used in) / generated from financing activities
 
(329)
36
(241)
Effects of exchange rate changes on cash and cash equivalents
 
(35)
(7)
(21)
Net (decrease) /  increase in cash and cash equivalents
 
(196)
23
234
Cash and cash equivalents at beginning of period
 
543
309
309
Cash and cash equivalents at end of period
 
347
332
543
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
1.     Basis of preparation
 
 
The condensed consolidated financial statements have been prepared in accordance with the Disclosure Guidance and Transparency Rules sourcebook of the UK's Financial Conduct Authority and in accordance with UK-adopted IAS 34 'Interim Financial Reporting'. The condensed consolidated financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2024, which were prepared in accordance with UK-adopted International Accounting Standards and with the requirements of the Companies Act 2006 and in accordance with IFRS accounting standards as issued by the International Accounting Standards Board (IASB). In respect of accounting standards applicable to the Group, there is no difference between UK-adopted IASs and IFRS accounting standards as issued by the IASB.
 
The condensed consolidated financial statements have also been prepared in accordance with the accounting policies set out in the 2024 Annual Report and have been prepared under the historical cost convention as modified by the revaluation of certain financial assets and liabilities (including derivative financial instruments) at fair value. No new standards and interpretations that apply to annual reporting periods beginning on or after 1 January 2025 have had a material impact on the financial position of the Group.
 
In assessing the Group's ability to continue as a going concern for the period until 31 December 2026, the Board analysed a variety of downside scenarios, including a severe but plausible scenario, where the Group is impacted by a combination of all principal risks from H2 2024, as well as reverse stress testing to identify what would be required to either breach covenants or run out of liquidity. The severe but plausible scenario modelled a severe reduction in revenue, profit and operating cash flow from risks continuing throughout 2026. At 30 June 2025, the Group had available liquidity of c£1.2bn, comprising central cash balances and the undrawn element of its $1.8bn Revolving Credit Facilities (RCFs) maturing February and June 2028, but which have options to extend the maturities until 2030. Even under a severe downside case, the Group would maintain comfortable liquidity headroom and sufficient headroom against covenant requirements during the period under assessment even before modelling the mitigating effect of actions that management would take in the event that these downside risks were to crystallise. The directors concluded that the likelihood of the reverse stress test scenario was remote.
 
The directors have confirmed that they have a reasonable expectation that the Group has adequate resources to continue in operational existence and to meet its liabilities as they fall due for the assessment period to 31 December 2026. The condensed consolidated financial statements have therefore been prepared on a going concern basis.
 
The preparation of condensed consolidated financial statements requires the use of certain critical accounting assumptions. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas requiring a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the condensed consolidated financial statements, have been set out in the 2024 Annual Report.
 
The financial information for the year ended 31 December 2024 does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The independent auditors' report on the full financial statements for the year ended 31 December 2024 was unqualified and did not contain an emphasis of matter paragraph or any statement under section 498 of the Companies Act 2006. The condensed consolidated financial statements and related notes for the six months to 30 June 2025 are unaudited but have been reviewed by the auditors and their independent review opinion is included at the end of these condensed consolidated financial statements.
 
Operating segments - In January 2025, the Group announced that Workforce Skills would evolve to become Enterprise Learning and Skills, incorporating our IT Pro business which was previously within Higher Education. Comparative figures for 2024 have been restated to reflect this move between segments.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
1.     Basis of preparation continued
 
Share buy back - On 27 February 2025, the Board approved a £350m share buyback programme in order to return capital to shareholders. Refer to the financial review for an update on the amounts bought back during the period.
 
2.     Segment information
 
The Group has five main global business units, which are each considered separate operating segments for management and reporting purposes. These five business units are Assessment & Qualifications, Virtual Learning, English Language Learning, Higher Education and Enterprise Learning and Skills. In January 2025, the Group announced that Workforce Skills would evolve to become Enterprise Learning and Skills, incorporating our IT Pro business which was previously within Higher Education. Comparative figures have been restated to reflect the move between segments, resulting in £22m of sales and £6m of adjusted operating profit being transferred from Higher Education to Enterprise Learning and Skills for the six months ended 30 June 2024 and £45m of sales and £12m of adjusted operating profit for the year ended 31 December 2024.
 
 
 
 
 
 
 
all figures in £ millions
 
2025
20241
20241
 
 
half year
half year
full year
 
 
 
 
 
Sales
 
 
 
 
Assessment & Qualifications
 
802
811
1,591
Virtual Learning
 
242
254
489
English Language Learning
 
171
188
420
Enterprise Learning and Skills
 
170
165
271
Higher Education
 
337
336
781
Total sales
 
1,722
1,754
3,552
 
 
 
 
 
Adjusted operating profit
 
 
 
 
Assessment & Qualifications
 
170
187
368
Virtual Learning
 
39
31
66
English Language Learning
 
(7)
4
50
Enterprise Learning and Skills
 
43
35
20
Higher Education
 
(3)
(7)
96
Total adjusted operating profit
242
250
600
 
1. Comparative amounts have been restated to reflect the move between operating segments.
 
There were no material inter-segment sales.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
2.     Segment information continued
 
The following table reconciles the Group's measure of segmental performance, adjusted operating profit, to statutory operating profit:
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Adjusted operating profit
 
242
250
600
Cost of major reorganisation
 
-
-
2
Intangible charges
 
(20)
(20)
(41)
UK pension discretionary increases
 
-
(5)
(13)
Other net gains and losses
 
7
(6)
(7)
Property charges
 
11
-
-
Operating profit
240
219
541
 
Adjusted operating profit is one of the Group's key business performance measures. The measure includes the operating profit from the total business but excludes charges for acquired intangibles amortisation and impairment, acquisition related costs, gains and losses arising from disposals, the cost of major reorganisation where relevant, property charges and one-off costs related to the UK pension scheme.
 
Cost of major reorganisation - In the first half of 2025 and 2024, there were no costs of major reorganisation. In the second half of 2024, there was a release of £2m relating to amounts previously accrued.
 
Intangible amortisation - These represent charges relating to intangibles acquired through business combinations. These charges are excluded as they reflect past acquisition activity and do not necessarily reflect the current year performance of the Group. Intangible amortisation charges in the first half of 2025 were £20m compared to a charge of £20m in the equivalent period in 2024.
 
UK pension discretionary increases - Charges in 2024 relate to one-off pension increases awarded to certain cohorts of pensioners in response to the cost of living crisis. There were no such amounts in 2025.
 
Other net gains and losses - These represent profits and losses on the sale of subsidiaries, joint ventures, associates and other financial assets and are excluded from adjusted operating profit in order to show the performance of the Group on a more comparable basis year on year. Other net gains and losses also includes costs related to business closures and acquisitions. Other net gains and losses in the first half of 2025 relate to the gain on disposal of a business in our Higher Education division, a fair value gain relating to a previous disposal and  costs relating to prior year acquisitions and disposals. Other net gains and losses in 2024 relate to costs related to prior year acquisitions and disposals, partially offset by a gain on the partial disposal of our investment in an associate.
 
Property charges - In 2025, a gain of £11m relates to reversals of impairments of property assets that were previously impaired through property charges. There are no such charges in the first half of 2024.
 
Adjusted operating profit should not be regarded as a complete picture of the Group's financial performance. For example, adjusted operating profit includes the benefits of major reorganisation programmes but excludes the significant associated costs, and adjusted operating profit excludes costs related to acquisitions, and the amortisation of intangibles acquired in business combinations, but does not exclude the associated revenues. The Group's definition of adjusted operating profit may not be comparable to other similarly titled measures reported by other companies.
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
2.     Segment information continued
 
 
The Group derived revenue from the transfer of goods and services over time and at a point in time in the following major product lines: 
 

 
Assessment & Qualifications
Virtual Learning 
English Language
Learning
Enterprise Learning
and Skills
Higher Education
Total
all figures in £ millions  
 
 
 
 
 
 
 
 
 
2025 half year
Courseware
 
 
 
 
 
 
 
Products transferred at a point in time
 
24
-
55
18
75
172
Products and services transferred over time
 
12
-
4
-
262
278
 
 
36
-
59
18
337
450
Assessments
 
 
 
 
 
 
 
Products transferred at a point in time
 
86
-
4
2
-
92
Products and services transferred over time
 
680
-
91
129
-
900
 
 
766
-
95
131
-
992
Services
 
 
 
 
 
 
 
Products transferred at a point in time
 
-
-
8
-
-
8
Products and services transferred over time
 
-
242
9
21
-
272
 
 
-
242
17
21
-
280
 
 
 
 
 
 
 
 
Total sales
 
802
242
171
170
337
1,722
 
 
 
 
 
 
 
 
 
 
2024 half year1
Courseware
 
 
 
 
 
 
 
Products transferred at a point in time
 
28
-
60
22
69
179
Products and services transferred over time
 
9
-
6
-
267
282
 
 
37
-
66
22
336
461
Assessments
 
 
 
 
 
 
 
Products transferred at a point in time
 
93
-
3
3
-
99
Products and services transferred over time
 
681
-
97
120
-
898
 
 
774
-
100
123
-
997
Services
 
 
 
 
 
 
 
Products transferred at a point in time
 
-
-
12
-
-
12
Products and services transferred over time
 
-
254
10
20
-
284
 
 
-
254
22
20
-
296
 
 
 
 
 
 
 
 
Total sales
 
811
254
188
165
336
1,754
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Comparative amounts have been restated to reflect the move between operating segments.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
2.     Segment information continued
 

 
Assessment & Qualifications
Virtual Learning
English Language Learning
Enterprise Learning and Skills
Higher Education
Total
all figures in £ millions  
 
 
 
 
 
 
 
 
 
2024 full year1
Courseware
 
 
 
 
 
 
 
Products transferred at a point in time
 
56
-
142
46
185
429
Products and services transferred over time
 
17
-
13
-
596
626
 
 
73
-
155
46
781
1,055
Assessments
 
 
 
 
 
 
 
Products transferred at a point in time
 
184
-
11
5
-
200
Products and services transferred over time
 
1,334
-
198
179
-
1,711
 
 
1,518
-
209
184
-
1,911
Services
 
 
 
 
 
 
 
Products transferred at a point in time
 
-
-
35
-
-
35
Products and services transferred over time
 
-
489
21
41
-
551
 
 
-
489
56
41
-
586
 
 
 
 
 
 
 
 
Total sales
 
1,591
489
420
271
781
3,552
 
 
 
 
 
 
 
 
 
 
1. Comparative amounts have been restated to reflect the move between operating segments.
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
3.     Net finance income / costs
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Net finance costs
 
(22)
(7)
(31)
Net finance income in respect of retirement benefits
 
(12)
(11)
(21)
Interest on deferred and contingent consideration
 
-
1
2
Fair value movements on investments held at FVTPL
 
4
8
11
Net foreign exchange gains
 
3
-
3
Fair value movements on derivatives
 
3
(12)
(7)
Interest on provisions for uncertain tax positions
 
-
-
(2)
Adjusted net finance costs
 
(24)
(21)
(45)
 
 
 
 
 
Analysed as:
 
 
 
 
Finance costs
 
(47)
(57)
(112)
Finance income
 
25
50
81
Net finance costs
 
(22)
(7)
(31)
 
Adjusted net finance costs is the finance cost measure used in calculating adjusted earnings. Adjusted net finance costs primarily consists of interest costs related to bonds, the RCF and lease liabilities, partially offset by interest income on cash deposits and lease receivables. 
 
The above table reconciles net finance income to adjusted net finance costs.
 
Net finance income relating to retirement benefits has been excluded from our adjusted earnings as we believe the income statement presentation does not reflect the economic substance of the underlying assets and liabilities. Also excluded are interest costs relating to acquisition or disposal transactions as it is considered part of the acquisition cost or disposal proceeds rather than being reflective of the underlying financing costs of the Group. Foreign exchange, fair value movements on investments classified as FVTPL and other gains and losses on derivatives are excluded from adjusted earnings as they represent short-term fluctuations in market value and are subject to significant volatility. Other gains and losses may not be realised in due course as it is normally the intention to hold the related instruments to maturity. Interest on certain tax provisions is excluded from our adjusted measure in order to mirror the treatment of the underlying tax item.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
4.     Income tax
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Income tax charge
 
(52)
(54)
(75)
Tax on cost of major reorganisation
 
-
-
1
Tax on other net gains and losses
 
1
-
-
Tax on intangible charges
 
(5)
(5)
(10)
Tax on UK pension discretionary increases
 
-
(1)
(3)
Tax on other net finance income
 
1
4
5
Tax amortisation benefit on goodwill and intangibles
 
1
2
4
State Aid provision release
 
-
-
(63)
Movement in provision for tax uncertainties
 
-
-
6
Other tax items
 
-
-
(1)
Adjusted income tax charge
 
(54)
(54)
(136)
 
 
 
 
 
Adjusted profit before tax
 
218
229
555
 
 
 
 
 
Tax rate reflected in statutory earnings
 
23.9%
25.5%
14.7%
Tax rate reflected in adjusted earnings
 
24.5%
23.6%
24.4%
 
The adjusted income tax charge excludes the tax benefit or charge on items that are excluded from the profit or loss before tax (see note 2). The adjusted tax charged in the period ended 30 June 2025 has been calculated by applying management's best estimate of the weighted average annual effective rate of tax which is expected to apply to the Group for the year ended 31 December 2025 to the adjusted profit before tax for the period ended 30 June 2025. Adjusting items have been tax effected on an item by item basis based on the applicable statutory tax rate in the country to which the item relates.
 
The tax benefit from tax deductible goodwill and intangibles is added to the adjusted income tax charge as this benefit more accurately aligns the adjusted tax charge with the expected rate of cash tax payments.
 
The statutory tax charge in the period ended 30 June 2025 is lower than the period ended 30 June 2024 due to an impairment reversal which is not taxable.
 
The Group is within the scope of the UK legislation in relation to Pillar Two which was effective from 1 January 2024. Based on the most recent forecast financial information available for the constituent entities in the Group, the Pillar Two effective tax rates in most of the jurisdictions in which the Group operates are above 15%. However, there are a limited number of jurisdictions where the transitional safe harbour relief does not apply, including jurisdictions that may not meet the 16% effective tax rate threshold required to qualify for the effective tax rate safe harbour test in FY25. In these jurisdictions,  the Pillar Two effective tax rate is close to 15%. The Group does not expect a material exposure to Pillar Two income taxes in those jurisdictions.
 
In the first half of 2025, a repayment of £97m was received from HMRC in respect of State Aid. This repayment is a result of the Court of Justice of the European Union ('CJEU') handing down its decision on 19 September 2024 determining that the United Kingdom controlled foreign company group financing partial exemption ('FCPE') did not constitute State Aid, thereby resulting in a refund of the £97m of tax paid (plus interest) under the Charging Notices issued by HMRC in 2021.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
5.     Earnings per share
 
 
Basic earnings per share is calculated by dividing the profit or loss attributable to equity shareholders of the company (earnings) by the weighted average number of ordinary shares in issue during the period, excluding ordinary shares purchased by the company and held as treasury shares. Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares to take account of all dilutive potential ordinary shares and adjusting the profit attributable, if applicable, to account for any tax consequences that might arise from conversion of those shares.
 
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Earnings for the period
 
166
158
435
Non-controlling interest
 
(2)
(1)
(1)
Earnings attributable to equity shareholders
 
164
157
434
 
 
 
 
 
Weighted average number of shares (millions)
 
661.5
680.5
673.0
Effect of dilutive share options (millions)
 
9.2
6.9
11.0
Weighted average number of shares (millions) for diluted earnings
 
670.7
687.4
684.0
 
 
 
 
 
Earnings per share (in pence per share)
 
 
 
 
Basic
 
24.8p
23.1p
64.5p
Diluted
 
24.5p
22.8p
63.5p
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
6.     Adjusted earnings per share
 
In order to show results from operating activities on a consistent basis, an adjusted earnings per share is presented which excludes certain items as set out below.
 
Adjusted earnings is a non-GAAP financial measure and is included as it is a key financial measure used by management to evaluate performance and allocate resources to business segments. The measure also enables users of the accounts to more easily, and consistently, track the underlying operational performance of the Group and its business segments over time by separating out those items of income and expenditure relating to acquisition and disposal transactions, major reorganisation programmes and certain other items that are also not representative of underlying performance (see notes 2, 3 and 4 for further information and reconciliation to equivalent statutory measures). The adjusted earnings per share includes both continuing and discontinued businesses on an undiluted basis when relevant. The company's definition of adjusted earnings per share may not be comparable to other similarly titled measures reported by other companies.
 
 
all figures in £ millions
note
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Adjusted operating profit
2
242
250
600
Adjusted net finance costs
3
(24)
(21)
(45)
Adjusted income tax
4
(54)
(54)
(136)
Non-controlling interest
 
(2)
(1)
(1)
Adjusted earnings
 
162
174
418
Weighted average number of shares (millions)
 
661.5
680.5
673.0
Weighted average number of shares (millions) for diluted earnings
 
670.7
687.4
684.0
Adjusted earnings per share - basic
 
24.5p
25.6p
62.1p
Adjusted earnings per share - diluted
 
24.2p
25.3p
61.1p
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
7.     Dividends
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Amounts recognised as distributions to equity shareholders in the period
 
110
107
156
 
The directors are declaring an interim dividend of 7.8p per equity share, payable on 15 September 2025 to shareholders on the register at the close of business on 15 August 2025. This interim dividend, which will absorb an estimated £51m of shareholders' funds, has not been included as a liability as at 30 June 2025.
 
8.     Exchange rates
 
Pearson earns a significant proportion of its sales and profits in overseas currencies, the most important being the US dollar. The relevant rates are as follows:
 
 
 
 
 
 
 
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Average rate for profits
 
1.31
1.26
1.28
Period end rate
 
1.37
1.26
1.25
 
 
9.     Non-current intangible assets
 
  
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Goodwill
 
2,285
2,436
2,437
Other intangibles
 
524
614
589
Non-current intangible assets
 
2,809
3,050
3,026
 
There were no significant acquisitions or disposals in the first half of 2025 or 2024.
 
Other movements in the goodwill balance relate to foreign exchange differences. Other movements in the intangibles balance relate to additions, amortisation and foreign exchange differences.
 
The Group has assessed its remaining goodwill and intangibles for impairment triggers and concluded that a full goodwill impairment review is not required at 30 June 2025.
 
The 2024 Annual Report sets out the key assumptions by segment. The discount rate, perpetuity growth rate and other assumptions used in the impairment review, and the sensitivity to changes in those assumptions remain broadly the same as the position outlined in the 2024 Annual Report. 
 
There were no impairments to acquisition related or other intangibles in the first half of 2025 or 2024. 
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
10.     Net debt
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Non-current assets
 
 
 
 
Derivative financial instruments
 
16
4
20
Trade and other receivables - investment in finance lease
 
55
73
64
Current assets
 
 
 
 
Derivative financial instruments
 
38
55
31
Trade and other receivables - investment in finance lease
 
19
19
19
Cash and cash equivalents (excluding overdrafts)
 
347
332
543
Non-current liabilities
 
 
 
 
Borrowings
 
(1,426)
(1,300)
(1,157)
Derivative financial instruments
 
(3)
(3)
(4)
Current liabilities
 
 
 
 
Borrowings
 
(62)
(313)
(315)
Derivative financial instruments
 
(11)
(44)
(54)
Net debt
 
(1,027)
(1,177)
(853)
 
Included in borrowings at 30 June 2025 are lease liabilities of £481m (non-current £419m, current £62m). This compares to lease liabilities of £521m (non-current £458m, current £63m) at 30 June 2024 and £517m (non-current £452m, current £65m) at 31 December 2024. The net lease liability at 30 June 2025 after including the investment in finance leases noted above was £407m (2024 half year: £429m, 2024 full year: £434m). Net debt excluding net lease liabilities is £620m (2024 half year: £748m, 2024 full year: £419m).
 
In 2025, the movement on borrowings from 31 December 2024 primarily reflects the repayment of the €300m bond offset by the drawdown of £300m on the RCF.
 
For the purposes of the cash flow statement, cash and cash equivalents are presented net of overdrafts of £nil (at 30 June 2024: £nil; 31 December 2024: £nil) which are repayable on demand. These overdrafts are excluded from cash and cash equivalents disclosed on the balance sheet.
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
11.     Classification of assets and liabilities measured at fair value
 
 
---Level 1---
Level 2
---Level 3---
 
Total fair value
all figures in £ millions
FVOCI
Investments
FVTPL - Cash
and cash equivalents
Derivatives
FVOCI
Investments
FVTPL- Investments and Other
 
 
 
 
 
 
 
 
 
2025 half year
 
 
 
 
 
 
 
Investments in listed and unlisted securities
1
-
-
23
102
126
Cash and cash equivalents
-
37
-
-
-
37
Derivative financial instruments
-
-
54
-
-
54
Deferred and contingent consideration
-
-
-
-
12
12
Total financial assets held at fair value
1
37
54
23
114
229
 
 
 
 
 
 
 
Derivative financial instruments
-
-
(14)
-
-
(14)
Deferred and contingent consideration
-
-
-
-
(1)
(1)
Total financial liabilities held at fair value
-
-
(14)
-
(1)
(15)
 
 
 
 
 
 
 
 
2024 half year
 
 
 
 
 
 
 
Investments in listed and unlisted securities
-
-
-
26
115
141
Cash and cash equivalents
-
42
-
-
-
42
Derivative financial instruments
-
-
59
-
-
59
Deferred and contingent consideration
-
-
-
-
12
12
Total financial assets held at fair value
-
42
59
26
127
254
 
 
 
 
 
 
 
Derivative financial instruments
-
-
(47)
-
-
(47)
Deferred and contingent consideration
-
-
-
-
(21)
(21)
Total financial liabilities held at fair value
 
-
(47)
-
(21)
(68)
 
 
 
 
 
 
 
 
2024 full year
 
 
 
 
 
 
 
Investments in listed and unlisted securities
6
-
-
22
113
141
Cash and cash equivalents
-
62
-
-
-
62
Derivative financial instruments
-
-
51
-
-
51
Deferred and contingent consideration
-
-
-
-
12
12
Total financial assets held at fair value
6
62
51
22
125
266
 
 
 
 
 
 
 
Derivative financial instruments
-
-
(58)
-
-
(58)
Deferred and contingent consideration
-
-
-
-
(1)
(1)
Total financial liabilities held at fair value
-
-
(58)
-
(1)
(59)
 
 
 
 
 
 
 
 
  
Level 1 valuations are based on unadjusted quoted prices in active markets for identical financial instruments. Cash and cash equivalents include money market funds which are treated as FVTPL under IFRS 9 with the fair value movements recognised as finance income or cost.
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
11.     Classification of assets and liabilities measured at fair value continued
 
The fair values of level 2 assets and liabilities are determined by reference to market data and established estimation techniques such as discounted cash flow and option valuation models. Within level 3 assets, the fair value of our investments in unlisted securities are determined by reference to the financial performance of the underlying asset and amounts realised on the sale of similar assets. Individually these assets are immaterial and therefore no sensitivities have been disclosed.
 
Level 3 assets also include the contingent consideration receivable in respect of the sale of the POLS business, which comprises a 27.5% share of positive adjusted EBITDA in each calendar year for 6 years from the disposal date and 27.5% of the proceeds received by the purchaser in relation to any future monetisation event. The valuation of the contingent consideration has been determined on the basis of a discounted cash flow model, and valued by a third-party specialist. The key inputs into the discounted cash flow model are the estimates of adjusted EBITDA for the 6 year period and the estimate of the valuation of the business thereafter. Reasonably possible changes in assumptions for the inputs into the model would not have a material impact on the carrying value of the contingent consideration, and therefore sensitivities have not been disclosed. The contingent consideration payable in respect of prior year acquisitions is measured as the net present value of the expected cashflows.
 
The movements in fair values of level 3 financial assets measured at fair value, being principally the investments in unlisted securities and contingent consideration receivable, are shown in the table below. There have been no transfers in classification during 2025. In the second half of 2024, one of the investments held was listed, and therefore the investment of £6m was reclassified out of level 3 and into level 1.
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
At beginning of period
 
147
155
155
Exchange differences - OCI
 
(9)
1
2
Additions
 
5
9
9
Disposals and repayments
 
(1)
-
-
Reclassification out of level 3
 
-
-
(6)
Fair value movements - Finance costs
 
(4)
(8)
(11)
Fair value movements - Other net gain and losses
 
2
-
-
Fair value movements - OCI
 
(3)
(4)
(2)
At end of period
 
137
153
147
 
The movement in the total fair value of the total deferred and contingent consideration payable measured at fair value or amortised cost is shown in the table below. At 30 June 2025, this comprised £16m of consideration measured at amortised cost and £1m measured at fair value.
 
 
 
 
 
 
all figures in £ millions
 
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
At beginning of period
 
(22)
(57)
(57)
Exchange differences
 
1
(1)
-
Acquisitions
 
-
-
(1)
Fair value movements - Income Statement
 
-
(1)
(2)
Repayments
 
4
38
38
At end of period
 
(17)
(21)
(22)
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
11.     Classification of assets and liabilities measured at fair value continued
 
The market value of the Group's bonds is £683m (30 June 2024: £570m; 31 December 2024: £918m) compared to their carrying value of £708m (30 June 2024: £597m; 31 December 2024: £955m). For all other financial assets and liabilities, fair value is not materially different to carrying value.
 
12.     Cash flows
 
Operating cash flow and free cash flow are non-GAAP measures and have been disclosed as they are part of the Group's corporate and operating measures. These measures are presented in order to align the cash flows with corresponding adjusted profit measures. The table below reconciles the statutory profit and cash flow measures to the corresponding adjusted measures. The table on the next page reconciles operating cash flow to free cash flow to net debt. 
 
 
all figures in £ millions
Statutory measure
Cost of major reorganisation
Property charges
Other net gains and losses
UK pension discretionary increases
Intangible charges
Purchase / disposal of PPE and software
Net addition of right of use assets
Dividends from joint ventures and associates
Adjusted measure
 
 
 
 
 
 
 
                  2025 half year
Operating profit
240
-
(11)
(7)
-
20
-
-
-
242
Adjusted operating profit
Net cash generated from operations
188
-
-
9
-
-
(59)
(12)
-
126
Operating cash flow
 
 
 
 
 
                  2024 half year
Operating profit
219
-
-
6
5
20
-
-
-
250
Adjusted operating profit
Net cash generated from operations
185
5
-
3
-
-
(52)
(12)
-
129
Operating cash flow
 
 
 
 
 
                  2024 full year
Operating profit
541
(2)
-
7
13
41
-
-
-
600
Adjusted operating profit
Net cash generated from operations
811
8
-
5
-
-
(118)
(46)
2
662
Operating cash flow
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
12.     Cash flows continued
 
 
 
 
 
 
all figures in £ millions
note
2025
2024
2024
 
 
half year
half year
full year
 
 
 
 
 
Reconciliation of operating cash flow to closing net debt
 
 
 
 
 
 
 
 
Operating cash flow
 
126
129
662
Tax received / (paid)
 
35
(69)
(119)
Net finance costs paid
 
(5)
(28)
(45)
Cost paid for major reorganisation
 
-
(5)
(8)
Free cash flow
 
156
27
490
Dividends paid (including to non-controlling interest)
 
(110)
(107)
(156)
Net movement of funds from operations
 
46
(80)
334
Acquisitions and disposals
 
(9)
(54)
(58)
Net equity transactions
 
(227)
(313)
(351)
Other movements on financial instruments
 
16
14
(34)
Movement in net debt
 
(174)
(433)
(109)
Opening net debt
 
(853)
(744)
(744)
Closing net debt
10
(1,027)
(1,177)
(853)
 
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the period ended 30 June 2025
 
13.     Contingencies, tax uncertainties and other liabilities
 
There are Group contingent liabilities that arise in the normal course of business in respect of indemnities, warranties and guarantees in relation to former subsidiaries and in respect of guarantees in relation to subsidiaries, joint ventures and associates. In addition, there are contingent liabilities of the Group in respect of unsettled or disputed tax liabilities, legal claims, contract disputes, royalties, copyright fees, permissions and other rights. None of these claims are expected to result in a material gain or loss to the Group.
 
The Group is under assessment from the tax authorities in Brazil challenging the deduction for tax purposes of goodwill amortisation for the years 2012 to 2020. Similar assessments may be raised for other years. Potential total exposure (including possible interest and penalties) could be up to BRL 1,372m (£183m) for periods up to 30 June 2025, with additional potential exposure of BRL 46m (£6m) in relation to deductions expected to be taken in future periods. Such assessments are common in Brazil. The Group believes that the likelihood that the tax authorities will ultimately prevail is low and that the Group's position is strong. At present, the Group believes no provision is required.
 
 
14.     Related parties
 
Related party transactions in the six months ended 30 June 2025 were substantially the same in nature to those disclosed in note 36 of the Annual Report and Accounts for the year ended 31 December 2024. All related party transactions are on an arm's length basis. There were no other material related party transactions in the period that have materially affected the financial position or performance of the Group and no guarantees have been provided to related parties in the year.
 
 
15.     Events after the balance sheet date
 
On 24 July 2025, the Group completed the acquisition of 100% of eDynamic Holdings LP ('eDynamic Learning'), a leading Career and Technical Education (CTE) curriculum solutions provider, having obtained all necessary approvals. This acquisition is aligned to Pearson's strategy, enabling Pearson to scale its position in the fast-growing Early Careers space and broaden capabilities in career-readiness solutions. The total consideration paid is £167m ($225m), plus net working capital adjustments. The net assets acquired will mainly comprise goodwill and intangible assets, expected principally to be customer contracts and content and technology recognised on acquisition. Since the acquisition closed subsequent to the half year date, it has not been reflected in the interim financial statements. Given the proximity of the acquisition to the publication of the half year results, the full valuation exercise has not been completed, and therefore, the financial impact on the Group's balance sheet has not been disclosed, but a provisional purchase price allocation will be included in the financial statements for the year ending 31 December 2025.
 
STATEMENT OF DIRECTORS' RESPONSIBILITIES
 
The directors confirm that these condensed consolidated financial statements have been prepared in accordance with UK-adopted International Accounting Standard 34 'Interim Financial Reporting' and that the interim management report includes a fair review of the information required by DTR 4.2.7 and DTR 4.2.8 namely:
 
 An indication of important events that have occurred during the first six months and their impact on the condensed consolidated financial statements, and a description of the principal risks and uncertainties for the remaining six months of the financial year; and
 
 Material related party transactions in the first six months and any material changes in related party transactions described in the 2024 Annual Report.
 
The directors of Pearson plc are listed in the 2024 Annual Report. There have been the following changes to the Board since the publication of the Annual Report.
 
Arden Hoffman - appointed 1 June 2025
 
A list of current directors is maintained on the Pearson plc website: www.pearsonplc.com. 
 
By order of the Board
 
 
Omar Abbosh
 
Chief Executive
 
31 July 2025
 
 
Sally Johnson
 
Chief Financial Officer
 
31 July 2025
 
 
INDEPENDENT REVIEW REPORT TO PEARSON PLC
 
Independent Review Report on the condensed consolidated interim financial statements
 
Conclusion
 
We have been engaged by Pearson plc (the Company) to review the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2025 which comprises the condensed consolidated income statement, the condensed consolidated statement of comprehensive income, the condensed consolidated balance sheet, the condensed consolidated statement of changes in equity, the condensed consolidate cash flow statement and the explanatory notes. We have read the other information contained in the half yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements. 
 
Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2025 is not prepared, in all material respects, in accordance with UK adopted International Accounting Standard 34 and the Disclosure Guidance and Transparency Rules of the United Kingdom's Financial Conduct Authority.
 
Basis for Conclusion
 
We conducted our review in accordance with International Standard on Review Engagements 2410 (UK) "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" (ISRE) issued by the Financial Reporting Council. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
 
As disclosed in note 1, the annual financial statements of the Group are prepared in accordance with UK adopted international accounting standards. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with UK adopted International Accounting Standard 34, "Interim Financial Reporting".
 
Conclusions Relating to Going Concern
 
Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis for Conclusion section of this report, nothing has come to our attention to suggest that management have inappropriately adopted the going concern basis of accounting or that management have identified material uncertainties relating to going concern that are not appropriately disclosed.
 
This conclusion is based on the review procedures performed in accordance with this ISRE, however future events or conditions may cause the entity to cease to continue as a going concern.
 
Responsibilities of the directors
 
The directors are responsible for preparing the half-yearly financial report in accordance with the Disclosure Guidance and Transparency Rules of the United Kingdom's Financial Conduct Authority.
 
In preparing the half-yearly financial report, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
 
Auditor's Responsibilities for the review of the financial information
 
In reviewing the half-yearly report, we are responsible for expressing to the Company a conclusion on the condensed set of financial statements in the half-yearly financial report. Our conclusion, including our Conclusions Relating to Going Concern, are based on procedures that are less extensive than audit procedures, as described in the Basis for Conclusion paragraph of this report.
 
Use of our report
 
This report is made solely to the company in accordance with guidance contained in International Standard on Review Engagements 2410 (UK) "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Financial Reporting Council. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our work, for this report, or for the conclusions we have formed.
 
Ernst & Young LLP
London
31 July 2025
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
PEARSON plc
 
 
Date: 01 August 2025
 
 
By: /s/ NATALIE WHITE
 
 
 
------------------------------------
 
Natalie White
 
Deputy Company Secretary

FAQ

How much capital is Scienture Holdings (SCNX) seeking in this private placement?

$3.0 million in equity securities.

What amount has Scienture already sold?

The company has sold $1.3 million, leaving $1.7 million available.

When did the offering under Form D begin?

The first sale occurred on 18 July 2025.

Are any sales commissions or broker fees associated with this offering?

No. The filing discloses $0 in commissions or finder’s fees.

What is the minimum investment size for the SCNX offering?

Each outside investor must invest at least $50,000.

How will Scienture use the proceeds?

For general working capital; no funds are earmarked for executive compensation.

Which regulatory exemptions is the company relying on?

Regulation D Rule 506(b) and Section 4(a)(5) of the Securities Act.
Pearson

NYSE:PSO

PSO Rankings

PSO Latest News

PSO Latest SEC Filings

PSO Stock Data

9.20B
650.77M
0.12%
2.99%
0.14%
Publishing
Communication Services
Link
United Kingdom
London